Amdocs (DOX) is preparing to present at the 5th TestMu Conference on August 19, 2026, where Amdocs Studios CTO and Head of Quality Engineering Studio, Dror Avrilingi, is scheduled to speak about the company's quality engineering focus.
Against this backdrop, Amdocs' share price has moved to US$62.91, with a 1 month share price return of 10.72% and a 7 day share price return of 2.46%. However, the share price return year to date is down 21.52% and the 1 year total shareholder return is down 24.02%, which points to shorter term momentum building after a tougher longer term run for investors.
Scan Amdocs alongside other software and telecom service stocks that quality filters already narrowed down to 19 high quality undiscovered gems .
So, after a sharp short term rebound but weaker longer term returns for Amdocs, is the market now underpricing a solid software and services business, or correctly discounting future risks? The valuation numbers provide a clearer indication next.
Most Popular Narrative: 23.3% Undervalued
Amdocs is trading at $62.91 against a narrative fair value of $82.03, which frames the stock as materially undervalued in that analysis.
Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12-month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.
Want to see what sits behind that $82.03 figure? The narrative leans on recurring cash flows, projected earnings expansion and a profitability profile that assumes steady margins over time.
Result: Fair Value of $82.03 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Amdocs narrative could be challenged if GenAI projects do not translate into customer spending, or if telecom clients further tighten budgets and delay contracts.
Find out about the key risks to this Amdocs narrative.
Next Steps
Given the mixed sentiment around Amdocs, with clear concerns alongside some optimism, it may be useful to move quickly and examine the data for yourself. Start by weighing the 4 key rewards and 1 important warning sign .
Looking for more investment ideas beyond Amdocs?
If you only focus on Amdocs, you could miss other stocks that better match your risk level and income goals, so consider putting the wider market to work for you.
-
Spot potential turnaround opportunities early by scanning the 22 elite penny stocks with strong financials that pass strict financial quality filters.
-
Target value focused ideas by reviewing the 44 high quality undervalued stocks that combine quality fundamentals with pricing that appears attractive according to the screener criteria.
-
Prioritise resilience and sleep-at-night holdings by assessing the 74 resilient stocks with low risk scores with more defensively rated profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DOX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
